|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
TWI682941B
(zh)
*
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
MX379030B
(es)
|
2013-12-17 |
2025-03-10 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI754319B
(zh)
*
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
ES2809455T3
(es)
*
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
KR102659123B1
(ko)
|
2014-11-24 |
2024-04-22 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 cd3 복합체를 발현하는 비인간 동물
|
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
|
|
SG11201704283PA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016110576A1
(en)
|
2015-01-08 |
2016-07-14 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
|
HRP20231134T1
(hr)
|
2015-06-16 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
|
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US11612149B2
(en)
*
|
2015-07-10 |
2023-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Non-human animal having human CD3 gene substituted for endogenous CD3 gene
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
KR102777500B1
(ko)
|
2015-09-23 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
최적화된 항-cd3 이중특이적 항체 및 이의 용도
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
HUE063377T2
(hu)
*
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
US20170174781A1
(en)
*
|
2015-12-22 |
2017-06-22 |
Regeneron Pharmaceuticals, Inc. |
Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
|
|
JP2019506155A
(ja)
|
2016-01-12 |
2019-03-07 |
クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ |
治療分子
|
|
SG10202010156XA
(en)
|
2016-04-20 |
2020-11-27 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
MX2018012868A
(es)
|
2016-04-20 |
2019-03-11 |
Regeneron Pharma |
Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
|
|
GB201607968D0
(en)
|
2016-05-06 |
2016-06-22 |
Crescendo Biolog Ltd |
Chimeric antigen receptor
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
WO2017210485A1
(en)
*
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
MA45255A
(fr)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
|
CN109641049B
(zh)
*
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MY200988A
(en)
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
US10738130B2
(en)
*
|
2016-09-23 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
KR20190074300A
(ko)
*
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
JP7267921B2
(ja)
|
2017-01-06 |
2023-05-02 |
クレシェンド・バイオロジックス・リミテッド |
プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
|
|
KR20240011262A
(ko)
|
2017-02-21 |
2024-01-25 |
리제너론 파아마슈티컬스, 인크. |
폐암의 치료를 위한 항-pd-1 항체
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JOP20190222A1
(ar)
*
|
2017-04-11 |
2019-09-24 |
Zymeworks Inc |
الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
GB201711068D0
(en)
|
2017-07-10 |
2017-08-23 |
Crescendo Biologics Ltd |
Therapeutic molecules binding PSMA
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
EP3658125A4
(en)
*
|
2017-07-28 |
2021-04-28 |
National University of Singapore |
BIOMOLECULAR COMPOSITES INCLUDING MODIFIED CELL PHANTOMS
|
|
CN113896797B
(zh)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CA3082297A1
(en)
|
2017-11-13 |
2019-05-16 |
Crescendo Biologics Limited |
Molecules that bind to cd137 and psma
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
|
GB201802573D0
(en)
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
FI3765525T3
(fi)
*
|
2018-03-13 |
2023-10-16 |
Zymeworks Bc Inc |
Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
EP3569617A1
(en)
*
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
PT3844189T
(pt)
|
2018-08-31 |
2025-01-29 |
Regeneron Pharma |
Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
CN109836502B
(zh)
*
|
2018-11-12 |
2021-09-07 |
浙江大学 |
一种双特异性抗体及其应用
|
|
PL3857237T3
(pl)
|
2019-01-16 |
2023-07-10 |
Regeneron Pharmaceuticals, Inc. |
Sposoby charakteryzowania mostka disiarczkowego
|
|
CN115093481A
(zh)
*
|
2019-01-28 |
2022-09-23 |
正大天晴药业集团股份有限公司 |
新型双特异性cd3/cd20多肽复合物
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2020156405A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel bispecific cd3/cd20 polypeptide complexes
|
|
MA54945A
(fr)
|
2019-02-12 |
2021-12-22 |
Regeneron Pharma |
Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
AU2020275406A1
(en)
|
2019-05-13 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
|
IL291020B2
(en)
|
2019-09-24 |
2025-04-01 |
Regeneron Pharma |
Systems and methods for use in chromatography and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
JP7809650B2
(ja)
|
2020-05-01 |
2026-02-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療用タンパク質に対する中和抗体アッセイ
|
|
BR112022022730A2
(pt)
|
2020-05-08 |
2023-02-14 |
Genmab As |
Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2022022464A1
(zh)
|
2020-07-27 |
2022-02-03 |
正大天晴药业集团股份有限公司 |
新型双特异性抗cd3/cd20多肽复合物配制剂
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
IL300828A
(en)
|
2020-08-31 |
2023-04-01 |
Regeneron Pharma |
Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
|
|
BR112023004216A2
(pt)
|
2020-09-10 |
2023-04-11 |
Genmab As |
Método para tratar linfoma folicular em um sujeito humano
|
|
US20230312758A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
EP4210746A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
EP4210744A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
WO2022072762A1
(en)
|
2020-10-02 |
2022-04-07 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
|
KR20230095113A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
|
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
RS66868B1
(sr)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharma |
Kompozicije i postupci za lečenje sindroma oslobađanja citokina
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
WO2022189667A1
(en)
|
2021-03-12 |
2022-09-15 |
Genmab A/S |
Non-activating antibody variants
|
|
CA3211302A1
(en)
|
2021-03-26 |
2022-09-29 |
Ross Kenyon |
Methods and systems for developing mixing protocols
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
JP2024538673A
(ja)
|
2021-10-07 |
2024-10-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨモデリング及び制御のシステム及び方法
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
IL312813A
(en)
|
2021-11-24 |
2024-07-01 |
Regeneron Pharma |
Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
|
|
IL313864A
(en)
|
2022-01-07 |
2024-08-01 |
Regeneron Pharma |
Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
|
|
IL315405A
(en)
|
2022-03-17 |
2024-11-01 |
Regeneron Pharma |
Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
CA3247475A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
|
|
EP4508086A1
(en)
|
2022-04-13 |
2025-02-19 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
|
WO2023214960A1
(en)
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Biochemical assays for therapeutic proteins
|
|
CA3253038A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
|
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
CN119546644A
(zh)
|
2022-05-18 |
2025-02-28 |
瑞泽恩制药公司 |
结合cd38和4-1bb的多特异性抗原结合分子及其用途
|
|
JP2025530983A
(ja)
|
2022-08-02 |
2025-09-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗ｐｓｍａ×抗ｃｄ２８抗体を抗ｐｄ－１抗体と組み合わせて、転移性去勢抵抗性前立腺癌を治療する方法
|
|
KR20250052419A
(ko)
*
|
2022-08-19 |
2025-04-18 |
일라이 릴리 앤드 캄파니 |
Pd-1 효능제 항체, 및 pd-1 효능제 항체에 의한 자가면역 질환의 치료 방법
|
|
CN120418653A
(zh)
|
2022-12-16 |
2025-08-01 |
里珍纳龙药品有限公司 |
评估色谱柱完整性的方法和系统
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
JP2026506095A
(ja)
|
2023-02-17 |
2026-02-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
GEAP202616846A
(en)
*
|
2023-03-10 |
2026-01-12 |
Biocad Joint Stock Co |
Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
KR20260049559A
(ko)
|
2023-08-02 |
2026-04-14 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD28 항체를 이용한 투명 세포 신세포 암종의 치료 방법
|
|
CN121604974A
(zh)
|
2023-08-02 |
2026-03-03 |
瑞泽恩制药公司 |
用双特异性抗psma x抗CD28抗体治疗转移性去势抵抗性前列腺癌的方法
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
TW202542187A
(zh)
|
2023-12-12 |
2025-11-01 |
美商再生元醫藥公司 |
以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026059917A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors
|
|
WO2026059920A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors
|
|
WO2026059923A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
|
|
WO2026059921A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
|
|
WO2026059919A1
(en)
|
2024-09-10 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|